The role of lncRNA CASC2 on prognosis of malignant tumors: a meta-analysis and bioinformatics.
The role of lncRNA CASC2 on prognosis of malignant tumors: a meta-analysis and bioinformatics.
复制标题
lncRNA CASC2对恶性肿瘤预后的作用：荟萃分析和生物信息学。
DOI：
10.2147/ott.s166132
复制
发表时间：
2018
影响因子：
4
通讯作者：
Cheng X
中科院分区：
文献类型：
--
作者：
Yu L;Chen S;Bao H;Zhang W;Liao M;Liang Q;Cheng X
Cancer susceptibility candidate 2 （cas2）是一种肿瘤抑制因子，在子宫内膜癌中首次被发现下调。越来越多的证据证明了CASC2在恶性肿瘤中的作用。然而，目前还没有系统和定量的评估。本研究旨在通过荟萃分析和生物信息学来评估CASC2在多种癌症中的作用。从开始到2017年12月1日，通过使用几个计算机化数据库对CASC2与肿瘤的关系进行了系统评估。计算合并HR和95% CI来总结效果。恶性肿瘤预后数据下载自The Cancer Genome Atlas (TCGA) project、OncoLnc、TANRIC和lncRNAtor数据库。本研究共纳入13项研究966例肿瘤患者，评估cas2在多发肿瘤中的预后价值及临床特征。荟萃分析结果显示，低表达水平的CASC2与较差的总生存率（OS）相关（合并HR=0.39, 95% CI: 0.28-0.53， P<0.0001）。cas2与肿瘤晚期淋巴结转移（TNM）分期、淋巴结转移（LNM）分期、T分期呈显著负相关（P<0.05）。性别、远处转移、高分化差异无统计学意义（P < 0.05）。在Kaplan-Meier曲线log-rank分析中，与低表达的患者相比，高表达的患者与更长的生存时间呈正相关（P<0.05），包括肾透明细胞癌、脑低级别胶质瘤、胰腺腺癌和肉瘤。这项荟萃分析的结果表明，低表达的CASC2与较差的癌症预后以及晚期TNM、LNM和T期相关。来自生物信息学分析的数据显示，在恶性肿瘤患者中，高表达的CASC2与较长的生存期有关。
Cancer susceptibility candidate 2 (CASC2) is characterized as a tumor suppressor, which was first identified to be downregulated in endometrial carcinoma. Accumulating evidence was provided to testify the function of CASC2 in malignant tumors. However, a systematic and quantitative assessment is not available. The present study was designed to evaluate the role of CASC2 in multiple carcinomas through meta-analysis and bioinformatics. A systematic assessment of the relationship of CASC2 with tumors was performed by using several computerized databases from inception to December 1, 2017. Pooled HR with 95% CI was calculated to summarize the effect. The data on prognosis of malignant tumors were also downloaded from The Cancer Genome Atlas (TCGA) project, OncoLnc, TANRIC and lncRNAtor database. A total of 13 studies with 966 cancer patients were pooled in the analysis to evaluate the prognostic value of CASC2 in multiple tumors and the clinical features. The results of the meta-analysis revealed that low expression levels of CASC2 were associated with poor overall survival (OS) (pooled HR=0.39, 95% CI: 0.28–0.53, P<0.0001). CASC2 obviously has a negative correlation with advanced tumor node metastasis (TNM) stage, lymph node metastasis (LNM) and T stage, respectively (P<0.05). There was, however, no significant difference in gender, distant metastasis and high differentiation (P>0.05). In the Kaplan–Meier curves with log-rank analysis, higher expression of CASC2 was positively correlated with longer survival time than patients with a lower level (P<0.05), including kidney renal clear cell carcinoma, brain lower grade glioma, pancreatic adenocarcinoma and sarcoma. Findings from this meta-analysis suggest that lower expression of CASC2 is associated with poorer prognosis of cancers, as well as advanced TNM, LNM and T stage. Data from the bioinformatics analysis revealed that higher expression of CASC2 was related to longer OS in patients with malignant tumors.